Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.
Publication
, Journal Article
Crawford, ED; Eisner, J; Persson, B-E
Published in: J Urol
March 2013
Duke Scholars
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
March 2013
Volume
189
Issue
3
Start / End Page
1168 / 1169
Location
United States
Related Subject Headings
- Urology & Nephrology
- Testosterone
- Tandem Mass Spectrometry
- Prostatic Neoplasms
- Male
- Humans
- Gonadotropin-Releasing Hormone
- Castration
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Crawford, E. D., Eisner, J., & Persson, B.-E. (2013). Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607. J Urol, 189(3), 1168–1169. https://doi.org/10.1016/j.juro.2012.09.090
Crawford, E David, Joel Eisner, and Bo-Eric Persson. “Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.” J Urol 189, no. 3 (March 2013): 1168–69. https://doi.org/10.1016/j.juro.2012.09.090.
Crawford ED, Eisner J, Persson B-E. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607. J Urol. 2013 Mar;189(3):1168–9.
Crawford, E. David, et al. “Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.” J Urol, vol. 189, no. 3, Mar. 2013, pp. 1168–69. Pubmed, doi:10.1016/j.juro.2012.09.090.
Crawford ED, Eisner J, Persson B-E. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607. J Urol. 2013 Mar;189(3):1168–1169.
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
March 2013
Volume
189
Issue
3
Start / End Page
1168 / 1169
Location
United States
Related Subject Headings
- Urology & Nephrology
- Testosterone
- Tandem Mass Spectrometry
- Prostatic Neoplasms
- Male
- Humans
- Gonadotropin-Releasing Hormone
- Castration
- 3202 Clinical sciences
- 1103 Clinical Sciences